SEC EDGARSEP 141 min read$PHVS

Lesage Anne sold $1.1M of PHVS

Lesage Anne (Chief Early Development) sold 30,000 shares of Pharvaris N.V. (PHVS) at $38.30 ($1.15M total) on 2026-09-10 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Lesage Anne

Published Sep 14, 2026, 4:29 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 14, 2026, 4:30 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$PHVS

Bearish

medium confidence

Mentioned

$PHVS

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$PHVSBearishLow

Why it matters

The disclosed sale provides fresh data on insider sentiment, potentially influencing short-term price action.

Market read

New insider sale may prompt traders to reassess PHVS's short-term outlook.

What to watch

Insider's 10b5-1 plan pre-arranged the sale, reducing informational value.

Relevance 5/10Novelty 8/10Timing: filing today

Background

SEC Form 4 filing reports an insider transaction for Pharvaris.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PHVSBearishMedium confidence

Context

Chief Early Development officer Lesage Anne sold 30,000 shares of Pharvaris (PHVS) for $1.149M on Sep 10, 2026.

Expected impact

Possible short-term dip of 2-3% as market digests the sale.

Evidence & confidence

Officer-level insider sold a sizable block, indicating possible concerns, but the amount is modest relative to market cap.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

Limited to U.S. biotech investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale may be routine portfolio rebalancing, not a bearish signal.

Key entities

person
Lesage Anne
Chief Early Development officer at Pharvaris
company
Pharvaris N.V.
Biotech company listed on Nasdaq under PHVS

Read at source ← All news

OCT 26

$PHVSHighAI 9/10

Bank of America backs Pharvaris on breakthrough for rare swelling disease

Bank of America upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing strong trial results for its HAE treatment drug, deucrictibant. The stock closed at $31.41 on Oct. 23. BofA sees substantial upside and notes positive feedback from doctors. The FDA decisions in 2027 could impact the stock.

finance.yahoo.com2 min

OCT 23

$PHVSMed

Pharvaris rises after BofA upgrades to Buy (PHVS:NASDAQ)

Pharvaris (PHVS) shares rose 3% premarket after BofA upgraded the stock to Buy from Neutral, citing its oral HAE potential. The brokerage kept its $44 price target. Pharvaris announced in September its.

seekingalpha.com1 min

OCT 23

$PHVSHigh

BofA upgrades Pharvaris stock rating on oral HAE treatment potential

BofA upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing potential in its oral HAE treatment. The stock trades at $30.68, up 10.6% in a week. Positive phase 3 data and strong analyst ratings highlight its prospects, despite risks like market adoption and competition.

investing.com1 min

OCT 9

$PHVSHighAI 9/10

Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027

Pharvaris (PHVS) reported that its Phase 3 study of deucrictibant XR for hereditary angioedema (HAE) met all endpoints, reducing attack rates by 83%. The company plans to file for FDA approval in H1 2027. PHVS stock closed at $31.12, up 0.58% in after-hours trading.

rttnews.com3 min

OCT 8

$PHVSMedAI 8/10

Pharvaris HAE drug shows faster symptom relief in Lancet study

Pharvaris' phase 3 study of deucrictibant IR for HAE attacks, published in The Lancet, met all endpoints, showing faster symptom relief and resolution than placebo. The drug was well-tolerated. FDA and EMA reviews are ongoing with decisions expected in 2027. According to the company, the study results support the drug's efficacy and safety.

investing.com5 min